Finding Something in Nothing: Patient-Centered Approaches to Resolve Emotional Blunting in Major Depressive Disorder (Credit Expired)
Emotional blunting (EB) is one of the most highly reported and subjectively disruptive symptoms in patients with major depressive disorder (MDD). As EB can inhibit the ability to achieve full functional recovery in affected patients, proactive screening for and monitoring of this symptom are critical in helping patients achieve complete and sustained improvement in MDD. This CME initiative utilizes expert-led discussion to tackle common challenges and misconceptions in recognizing and resolving EB. To provide context for the reasoning behind and feasibility of recommended faculty strategies, verbatims from interviews with real patients are integrated throughout.
This activity is designed to meet the needs of psychiatrists, primary care physicians, nurse practitioners, physician assistants, registered nurses, and other healthcare professionals involved in the diagnosis and long-term management of patients with MDD.
Upon completion of the educational activity, participants should be able to:
- Appraise the utility and practicality of available tools and strategies (e.g., Oxford Depression Questionnaire) to screen for and evaluate EB in MDD to select the most appropriate assessments to incorporate into routine practice.
- Evaluate published research and expert experience with pharmacological strategies (e.g., vortioxetine, bupropion) in the mitigation and/or resolution of EB to better facilitate complete recovery for patients with MDD.
- Discuss candidacy and expectations for antidepressant treatment and/or incorporation of non-pharmacologic approaches (e.g., cognitive behavioral therapy) in patients with emotional blunting in order to effectively counsel patients about available treatment options and optimize therapy based on individual patient needs.
Leslie Citrome, MD, MPH (Chair)
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College Valhalla, NY
Roger McIntyre, MD, FRCPC
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Professor, Psychiatry and Pharmacology
University of Toronto
Toronto, ON, CA
C. Brendan Montano, MD
Assistant Clinical Instructor, Department of Family Practice University of Connecticut
Internal Medicine and Mood Disorders
Credit for this program has expired. The accreditation information below is based on the activity release date.
This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.
In support of improving patient care, MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
MER designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
MER requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All relevant financial relationships have been mitigated by MER. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Planners’ and Managers’ Disclosure
MER planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.
Leslie Citrome, MD, MPH
- Consulting Fees: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Teva, University of Arizona, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research
- Speakers’ Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies
- Ownership Interest/Shareholder: Stocks (small number of shares of common stock): Bristol- Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago, stock options: Reviva
- Royalty/Patent Holder: Royalties: Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics)
Roger McIntyre, MD, FRCPC
- Grants/Research Support: CIHR/GACD/Chinese National Natural Research Foundation
- Consulting Fees: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen , Kris, Lundbeck, Otsuka, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Pfizer, Purdue, Sanofi, Sunovion, Takeda.
C. Brendan Montano, MD
- Grants/Research Support: AbbVie, Acadia, Adlon, Arbor, Avanir, Axsome, Biohaven, Eli Lilly, Idorsia, Neurana, Nutrasource, Otsuka, Relmada, Sage, Satsuma, Tonix
- Consulting Fees: AbbVie, Acadia, Arbor, Eisai, Sunovion, Supernus, Takeda
- Speakers’ Bureau: AbbVie, Eisai, Eli Lilly, Otsuka, Takeda
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from Takeda Pharmaceuticals.